Shares of Verve Therapeutics VERV surged 26.4% on Monday and continue to soar today after the company announced positive initial data from an early-stage study of its investigational candidate ...

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one ...

On the other hand, Verve Therapeutics VERV skyrocketed on positive data from a cholesterol study. Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY ...

Shares of Verve Therapeutics (NASDAQ:VERV) climbed for the second straight session on Tuesday after Cantor Fitzgerald upgraded the stock based on early-stage trial data the gene editing company ...

In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Verve Therapeutics (VERV – Research Report), with a price target of $16.00. The company’s shares closed ...

NASDAQ VERV opened at $4.97 on Monday. The stock has a market capitalization of $441.32 million, a PE ratio of -2.02 and a beta of 1.86. Verve Therapeutics has a 12-month low of $2.86 and a 12 ...

Gwen Walz, the wife of Minnesota Gov. and former Democratic vice presidential nominee Tim Walz (D), recently slammed Health and Human Services Secretary Robert F. Kennedy Jr. over his widely panned ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on Verve Therapeutics (VERV – Research Report), with a price target of $24.00. The company’s shares ...